D&B Report

STAR PHARMA (SAMPLE) LLC

Delivery Date: Jan 19, 2020

Subscriber No: 784111170 Ticket Key: 202001195007840267 Reference:

Identification		RIS	K
D-U-N-S Number:	53-442-0646	Ris	k Ev
Registration No.:	269350	Risl	
Address:	Opposite Emarat Petrol Station Abu Hail Road,Hor Al Anz,New Al Safiya Bldg,Suite No.2, Floor 03 Dubai Dubai United Arab Emirates	D& For <u>Fina</u> FYE	mer anci
Telephone(s):	(+971) 4 2680603 (+971) 4 2588101	Rev	
Facsimile(s):	(+971) 4 2624755	Tot	al A
E-Mail:	info@starph.com	Tot	
Website:	www.starph.com	Net	
Summary		Fina Cur Oui	rent
Type of Business:	Free Zone Establishment	Pro	
History:	Clear	Ret	urn
Start:	Oct 11, 1994	Tot	al D
Registration Date:	Oct 11, 1994	<u></u>	
Registration Period End Date:	Feb 13, 2021	Cur All Unit	moi
Control Date:	Oct 11, 1994	Onit	cui
Authorized Capital:	AED 3,000,000.00		
Issued Capital:	AED 3,000,000.00		
Paid-up Capital:	AED 3,000,000.00		
Line of Business:	Wholesales medical and hospital equipment		
SIC:	5047-0000 5122-0000		
Imports:	Yes		
Exports:	Yes		
Employees:	14 Estimated (Here)		
Risk Assessment			
Risk Indicator	3		

RISK SUMMARY	
Risk Evaluation	
Risk Indicator	3
D&B Rating	A3
Former Rating	2A3
Financial Summary	
FYE	Dec 31, 2019
Revenue	10,323,425
Net Worth	4,251,121
Total Asset	7,108,617
Total Liabilities	2,857,496
Net Profit after Tax	2,751,121
Financial Ratios	
Current Ratio	3.14
Quick Ratio	2.05
Profit Margin / Return on Sales	26.65%
Return on Assets	38.70%
Total Debt to Net Worth	67.22%

ency

Einancial Strength

Risk Indicator

Α

3

Based on net worth

Fair (Slightly greater than average Risk - Monitor closely)

onetary amounts quoted in this report are shown in Arab Emirates Durham (AED), unless otherwise stated.

The Dun & Bradstreet Rating of A3 indicates:

A Financial Strength of USD 600,000 - USD 1.2 million (Based on net worth) and a Risk Indicator which is Fair (Slightly greater than average Risk - Monitor closely).

4

Investigation Information

T

1

On Jan 08, 2020, Usha Gandhi Manager Operations Corporate Leisure, declined all information.

Fair V

All information about the subject has been obtained from the local sources, registry, existing database, website and web research as the subject has declined to provide any information ..

8 April 2019 an official correspondence email has been sent at popo.hartopo@stellatravel.co.uk however reply received from Jennifer Loong (Purchasing Manager- Malaysia, Singapore & Hong Kong).

She informed that Popo Hartopo has left the company and she will take over the purchasing for Malaysia, Singapore & Hong Kong. 9 April 2019 an official correspondence email has been sent at purchasingsupport@yalago.com however no reply received...

10 April 2019 an official correspondence email has been sent at virgine.michaud@dnata.com however no reply received..

STAR PHARMA (SAMPLE) LLC started its operations in Oct 11, 1994 and was registered on Oct 11, 1994 as a Free Zone Establishment. It was registered with the Registry of Companies and Businesses under the registration number 269350, Dubai, U A E Subject is registered in 'Department of Economic Development Board- Dubai'.

Chamber of commerce: Registered Address:

70574 Abu Hail Road,Hor Al Anz,New Al Safiya Bldg,Suite No.2, Floor 03 Opposite Emarat Petrol Station United Arab Emirates

Capital		
Authorized Capital:	AED 3,000,000.00	
Issued Capital:	AED 3,000,000.00	
Paid-up Capital:	AED 3,000,000.00 as of Feb 13, 2017	

Shareholders and Shareholdings

The following details represent the Full Shareholders List.

з

Shareholders
51.00
25.00
24.00
100

Total of Shareholders

Ordinary Shares

Auditors	
Auditor:	ERNST & YOUNG
LINKAGE	
Affiliates	
Total number of Affiliates: 1	
Name:	Imex Health FZC
Subject holds shares in affiliate:	50%
Branches	
Subject maintains 3 branch(es)	country wide.
Branch Tradestyle Name: Address:	AAA Shaikh Zayad Road,
Address.	Dubai
	United Arab Emirates
PRINCIPALS	
Executives	
Name: Current Title:	Deepak Parekh Manager Marketing
Current Title:	Manager Marketing
Name: Current Title:	Ivan Matthew Director
Name:	John Matthew
Current Title:	Managing Director
Other Current Title:	Chief Executive Officer
Founder of Subject:	Yes
Name:	Sean Myatt
Current Title:	Executive Accounts
 Wholesales drugs, prop Brand Names 	prietaries, and sundries (5122-0000)
Principal Name:	
	Mega Life Sciences, Australia
	Mega Life Sciences, Australia Distributor
Subject as:	
Subject as: Description:	Distributor
Subject as: Description: Principal Name:	Distributor Ginsomin, Pynocare & licare
Subject as: Description: Principal Name: Subject as:	Distributor Ginsomin, Pynocare & licare Bliss, India
Subject as: Description: Principal Name: Subject as: Description:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Principal Name: Subject as:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Principal Name: Subject as:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subjet as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINIMAX
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subjet as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms Import Terms:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX
Subjet as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms Import Terms:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms Import Terms:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms Import Terms: Sales Sales Territory	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINIMAX 100% India Kuwait United States Australia Canada bank transfer Letter of Credit
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms International: Import Terms: Sales Sales Territory Local: International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer Letter of Credit
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms International: Import Terms: Sales Sales Territory Local: International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer Letter of Credit 20% 80% Uganda Ghana Democratic Republic of Congo
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms International: Import ferms: Sales Sales Territory Local:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada 20% 80% Uganda Chana Democratic Republic of Congo
Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Principal Name: Subject as: Description: Purchases Purchasing Territory International: Imports from The subject imports products. Purchasing Terms International: Import Terms: Sales Sales Territory Local: International:	Distributor Ginsomin, Pynocare & licare Bliss, India Distributor TODAY Kuwait Saudi Pharma, Kuwait Distributor Loraday Daily Wellness, United States Distributor ARGINMAX 100% India Kuwait United States Australia Canada bank transfer Letter of Credit 20% 80% Uganda Ghana Democratic Republic of Congo

bank transfer cash Letter of Credit (at sight)

bank transfer cash Letter of Credit (at sight)

Selling Terms

Local Sales Terms:

Export Terms:

	mers maintains 1000 acco	ints / customers	
	Customers		
	KSPICO - Manufactur Department Store(s)	ar	
	Kuwait		
	Delmaw-Distributor		
	Uganda		
	50 % Sales		
	Gesto Distributor Kenya		
	Gulf Africa Distributo		
	Congo		
Suppl	iers		
	Bliss GVS Pharma Lto		
	102, Hyde Park, Andl India	eri	
_			
	K SPICO 5512, 13056		
	Kuwait		
	Mega Life Sciences		
	Australia		
Emple	oyees		
Emplo	oyee(s) - Curren		
	vees (here):	14 Estimated	
Employ	vees (nere).	14 Estimated	
Emplo	oyee(s) - Previou	3	
Year:		2014	
Total E	mployees:	12	
N.		2013	
Year: Total F	mployees:	11	
TOTAL	inployees.		
ISO C	ertificate / Tax Ir	centives	
ISO C	ertification		
Subjec	t was awarded:	ISO 9001 on Dec 28, 2004	
Insura	nce		
Compa		AIG	
LOC	ATION		
Curre	nt Location		
	premise:	12 hectare(s)	
	f Occupation:	Rented	
Locatio		Covered shop centre	
	es used as:	Administrative office	
riemis	es doeu as.	Hotel	
		Garage	
		Marketing office	

Abu Hail Road, Hor Al Anz, New Al Safiya Bldg, Suite No.2, Floor 03

Dubai, United Arab Emirates

Mailing Addres

Dubai, United Arab Emirates

FINANCIAL INFORMATION

Comparatives

Particulars	Fiscal Consolidated Dec 31, 2017 AED	Fiscal Consolidated Dec 31, 2018 AED	Fiscal Consolidated Dec 31, 2019 AED
Current Assets	4,225,621	5,544,694	6,395,863
Current Liabilities	992,792	1,079,342	2,040,129
Working Capital	3,232,829	4,465,352	4,355,734
Other Tangible Assets	401,494	348,792	712,754
Non-Current Liabilities	1,003,131	879,724	817,367
Tangible Net-Worth	2,631,192	3,934,420	4,251,121
Revenue	8,060,935	9,779,097	10,323,425
Profit (Loss) After Tax	2,070,735	2,664,222	2,751,12
Inventory	734,200	953,096	1,092,031
Cash & Bank	487,823	98,262	189,469
Accounts Receivable	2,636,762	3,686,968	3,985,536
Fixed Assets	401,494	348,792	712,754
Accounts Payable	494,165	800,159	777,684
Intangibles	0	0	(

Assets	Fiscal Consolidated Dec 31, 2017 AED	Fiscal Consolidated Dec 31, 2018 AED	Fiscal Consolidated Dec 31, 2019 AED
Cash	1,198	6,112	26
Cash & Bank	487,823	98,262	189,469
Inventory	734,200	953,096	1,092,03
Deposit-Short Term	19,500	25,500	48,500
Accounts Receivable	2,636,762	3,686,968	3,985,53
Other Receivables	95,619	153,999	167,299
Prepayments	20,869	84,755	263,833
Loans & Advances	3,800	47,700	80,840
Due from Releated Parties	177,668	286,873	568,094
Due from Shareholders	48.182	201,429	

UAE - SAMPLE REPORT - BIR.HTM

Total Current Assets	4,225,621	5,544,694	6,395,863
Leasehold Improvements	43,791	22,661	15,810
Transportation Vehicles	20,356	59,034	39,234
Furniture Fixtures & Fitting	34,675	31,725	55,613
Fixtures and Equipment	288,671	222,068	588,832
Computer	14,001	13,304	13,265
Total Fixed Assets	401,494	348,792	712,754
Total Investments	0	0	C
Total Other Assets	0	0	C
Total Intangibles	0	0	C
TOTAL ASSETS	4,627,115	5,893,486	7,108,617
Liabilities	Fiscal Consolidated Dec 31, 2017 AED	Fiscal Consolidated Dec 31, 2018 AED	Fiscal Consolidated Dec 31, 2019 AED
Accounts Payable	494,165	800,159	777,684
Creditors & Borrowings	100,000	100,000	827,212
Due to Customers		18,018	
Other Payables / Accruals	398,627	161,165	435,233
Total Current Liabilities	992,792	1,079,342	2,040,129
Creditors & Borrowings	900,000	800,000	700,000
Provident & Pensions	103,131	79,724	117,367
Total Non-Current Liabilities	1,003,131	879,724	817,367
TOTAL LIABILITIES	1,995,923	1,959,066	2,857,496
Capital	1,000,000	1,000,000	1,000,000
Legal Reserves	270,198	500,000	500,000
Retained Earnings (Loss)	1,360,994	2,434,420	2,751,121
TOTAL EQUITY	2,631,192	3,934,420	4,251,121
TOTAL LIABILITIES & EQUITY	4,627,115	5,893,486	7,108,617

Profit & Loss

Particulars	Fiscal Consolidated Dec 31, 2017 12 Month(s) AED	Fiscal Consolidated Dec 31, 2018 12 Month(s) AED	Fiscal Consolidated Dec 31, 2019 12 Month(s) AED
Revenue	8,060,935	9,779,097	10,323,425
Less: Cost of Sales	-3,073,925	-3,926,974	-3,756,414
Gross Profit (Loss)	4,987,010	5,852,123	6,567,011
Depreciation / Amortisation	-151,739	-199,987	-251,285
General Operating Expenses	-3,011,558	-3,099,954	-3,544,292
Other Non-Operating Income	267,022	181,284	81,499
Depreciation & Interest	-20,000	-69,244	-101,812
Net Profit (Loss) Before Taxation	2,070,735	2,664,222	2,751,121
Net Profit(Loss) after Tax	2,070,735	2,664,222	2,751,121
Net Profit (Loss) After Taxation & Extraordinary Items	2,070,735	2,664,222	2,751,121
Plus (Minus) Retained Earnings b/forward		2,664,222	2,751,121
Retained Earnings (Loss) c/forward		5,328,444	5,502,242

Accounts are audited by ERNST & YOUNG.

Particulars	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019
GROWTH TREND			
Sales Growth (%)		21.31	5.57
Net Profit Growth (%)		28.66	3.20
PROFITABILITY RATIOS			
Profit Margin (%)	25.69	27.24	26.65
Return on Assets (%)	44.75	45.21	38.70
Return on Net Worth (%)	78.70	67.72	64.72
LIQUIDITY RATIOS			
Current Ratio	4.26	5.14	3.14
Quick Ratio	3.15	3.51	2.0
EFFICIENCY RATIOS			
Collection Period (days)	118	136	139
Asset to Sales (%)	57.40	60.27	68.80
Sales to Inventory (times)	11	10	9
Fixed Assets to Net Worth (%)	15.26	8.87	16.7
INDEBTEDNESS RATIOS			
Short Term Debt to Net Worth (%)	38.00	27.00	48.00
Short Term Debt to Inventory (%)	135.22	113.25	186.8
Total Debt to Net Worth (%)	75.86	49.79	67.22

Customer Service

Inquiries should **always** contain the below minimum details:

- Full Company Name
- Full Headquarters Address
- Telephone Number
- Business Identification Number
- Contact Name
- Reference
- Order Date
- D&B Rating Glossary

D&B Rating - The D&B rating consists of two parts, the Financial Strength Indicator and the Risk Indicator.

For example: in the case of a 2A 4 rating, 2A means the financial strength of the business and the 4 is the risk indicator. The Risk Indicator is used in conjunction with the Financial Strength Indicator. The Risk Indicator reflects D&B's opinion of a company's

he has indicator is used in conjunction that the manage during in modulo. The issue indicator function bases optimate the object of the set of Risk Indicator

4	Significant level of risk	Take suitable assurances before extending credit
3	Greater than average risk	Proceed with transaction but monitor closely
2	Low risk	Proceed with transaction
1	Minimal risk	Proceed with transaction - offer terms required
-	Insufficient information to assign a risk indicator	No public information or D&B proprietary information available to indicate trading activity

The Financial Strength Indicator is based on either the Net Worth or Issued Capital. The table below contains the possible values.

Financial Strength Indicator

Financial Strength Indicator		Range	Range		
Net Worth	Capital	From	То		
5A	5AA	\$60 million	and greater		
4A	4AA	\$25 million	\$60 million		
3A	3AA	\$12 million	\$25 million		

UAE - SAMPLE REPORT - BIR.HTM

2A	2AA	\$2.5 million	\$12 million			
1A	1AA	\$1.2 million	\$2.5 million			
A	AA	\$600,000	\$1.2 million			
В	BB	\$345,000	\$600,000			
С	CC	\$175,000	\$345,000			
D	DD	\$120,000	\$175,000			
E	EE	\$60,000	\$120,000			
F	FF	\$35,000	\$60,000			
G	GG	\$15,000	\$35,000			
н	HH	0	\$15,000			
Alte	rnate Ratings Used Out of Business: Business has ceased to trade					
NB	New Business: Less than 24 months					
0	Financial Strength is undisclosed; or Assigned to companies that do not request credit in their normal activities (Bank, Brokerages, Insurance Co., Associations, Government, etc)					
N	Negative Net Worth					
FB	Foreign Branch					

BR Domestic Branch DS Assigned to records that require investigation before a rating can be assigned.

Name	Formula	Explanation	
Current Ratio (x)	Total Current Assets / Total Current Liabilities	This ratio shows the cover by current assets of short term creditors, and the higher the ratio the more assurance there is that payment of creditors can be met	
Solvency Ratio (%)	((Total Current + Deferred + Long Term Liabilities) / Tangible Net Worth) x 100	From this can be seen the extent to which the company is financed by creditors and debt rather than permanent finance. The higher the ratio the more likely it is that the debt (rither short term or long term) will be a burden to the company. The effect is higher interest changes, lower profits and a squeeze on liquidity to the disadvantage of creditors.	
Fixed Assets to Net Worth (%)	(Total Fixed Assets / Tangible Net Worth) x 100	The proportion of net worth that consists of fixed assets will vary greatly from industry to industry, but in general terms a company is under capitalised if fixed assets exceed net worth. In this case it is possible that the company has too much debt, and it should therefore be examined with care. If on the other hand fixed assets are much lower than net worth the company is over capitalised and is either extremely cautious or in a position to expand. Thus a ratio either well in excess of the median, or well below it, means that the company should be looked at with care.	
Current Liabilities to Net Worth (%)	(Total Current Liabilities / Tangible Net Worth) x 100	This contrasts the funds that creditors are temporarily risking with a company with the funds permanently invested by the owners. The higher the ratio the less security for creditors. Care should be exercised when selling to any company with creditors of less than one year exceeding two thirds of net worth	
Asset Turnover (%)	(Turnover / Total Assets(including intangibles)) x 100	This ratio measures how efficiently the company's management has been in generating sales from the assets at its disposal. The measure can vary considerably from industry to industry and should therefore g be judged according to the industry norm.	
Sales to net working capital (x)	Turnover / Net working capital	This ratio indicates whether a company is overtrading (handing an excessive volume of sales in relation to working capital). Companies with substantial sales gains often reach a level where their working capital becomes straimed. Even if they maintain an adequate total investment for the volume being generated (assets to sales) that investment may be so centred in fixed assets or other non-current item that it will be difficult to continue meeting all current obligations. A ratio falling into either an extremel high or low position may indicate potential problems.	

Confidentiality

CONFIDENTIAL THIS INFORMATION IS PROVIDED BY DUN & BRADSTREET SUBJECT TO THE TERMS AND CONDITIONS OF YOUR SUBSCRIPTION CONTRACT AND IS NOT TO BE DISCLOSED.

this report is forwarded to the Subscriber in strict confidence for the use by the Subscriber as one factor to consider in connection with credit and other business decisions. This report contains information compiled from information which Dun & Bradstreet does not control and which has not been verified unless otherwise indicated in this report. Dun & Bradstreet cannot accept responsibility for the accuracy, completeness or timeliness of the report. Dun & Bradstreet disclamma all liability for any loss or damage arising out of or in anyway related to the contents of this report. This material is confidential and proprietary to Dun & Bradstreet and/or third parties and may not be reproduced, published or disclosed to others without the express authorization of Dun & Bradstreet.

COPYRIGHT © 2020 DUN & BRADSTREET. THIS REPORT MAY NOT BE REPRODUCED IN WHOLE OR IN PART IN ANY FORM OR MANNER WHATSOEVER.

END OF REPORT